1 of 12

MediCheck

Fighting counterfeit drugs with trust and technology.

Team: MediCheck

2 of 12

42% of global counterfeit drugs circulate in Africa (WHO).

Over 267,000 people die annually from fake medication (UN).

Patients can’t verify authenticity.

Government systems like NAFDAC’s Green Book are manual and underused.

In Africa, drugs kill just as much as diseases do.

The Problem

3 of 12

Our Solution

Each drug gets a unique digital ID recorded on Hedera.

MediCheck - A decentralized platform that lets anyone verify any drug in seconds by combining AI and Hedera to create a tamper-proof, traceable drug supply chain.

Every transfer (factory → distributor → pharmacy → patient) is logged immutably.

Users scan QR code to confirm authenticity in real-time.

AI explains drug details and authenticity information in local languages.

4 of 12

Why Hedera?

Hedera provides the infrastructure for autonomous, trusted healthcare systems.

Hedera Consensus Service (HCS):

      • Provides tamper-proof timestamps for every event in the drug’s journey.
      • Enables cross-border traceability with low, predictable fees.
      • Guarantees ABFT finality — critical for medical authenticity records.

HCS-10 for Autonomous Agents:

      • Powers MediCheck’s AI verification agents that detect counterfeit anomalies automatically.
      • Agents communicate using HCS-10 messages to flag duplicates or suspicious drug IDs.
      • Builds a self-regulating, AI-driven monitoring network — faster than human inspection.

ESG Fit: Hedera’s carbon-negative network aligns with healthcare sustainability goals.

5 of 12

Market & Opportunity

Problem market

Opportunity market

Summary:

      • TAM: $200 B+ Global Counterfeit Drug Market → the problem we’re solving
      • SAM: $17 B+ African Pharmaceutical Market → where we’re targeting initial growth
      • SOM: $4 B+ Nigerian Pharmaceutical Market → our entry point for launch and scale

6 of 12

Product Architecture

TRL Level: Version-1 MVP live

7 of 12

Business and Revenue Model

B2B SaaS Model

      • Manufacturers subscribe to register and onboard their products onto MediCheck.
      • Pharmacies & insurance companies subscribe to advanced verification and traceability tools.
      • This ensures patients pay nothing, while stakeholders sustain the ecosystem.

8 of 12

Tokenomics & Community

Phase 2 (Post-hackathon):

      • Introduce a Verification Token (MVT) as a user incentive.
      • Patients earn tokens for verifying drugs → drives adoption.
      • Tokens redeemable for discounts or health benefits.
      • Enables governance participation by trusted stakeholders (manufacturers, NGOs).

​

Community Growth Strategy:

      • Partner with hospitals, pharmacies, and health NGOs.
      • Use educational campaigns to teach safe drug verification via MediCheck.

9 of 12

Traction & Milestones

Current Progress

      • MVP Built: Core platform developed for end-to-end drug verification and traceability.
      • AI Integration: Multilingual verification, result explanations, and patient chat support.
      • Stakeholder Dashboards: Functional dashboards for hospitals, manufacturers, and regulators.
      • Version 1 Live: First working version successfully deployed.

​

Next Steps

      • New Dashboards: Add pharmacy and insurer dashboards.
      • Stakeholder Onboarding: Onboard hospitals, pharmacies, and insurers to active use.
      • Regulatory Partnerships: Collaborate with agencies (e.g., NAFDAC) for compliance integration.
      • Platform Expansion: Upgrade MediCheck to a Progressive Web App (PWA) and mobile app for easy drug scanning and verification by patients.

10 of 12

Our Team

Jedidiah Okon Solomon

Project manager

Ogunnowo Timilehin

Backend Developer

Odumbo Abdulwaris

Frontend Developer

Mustapha Fadhlullah

Frontend Developer

Obadimeji David

AI/ML Engineer

Why Us:

      • Combined experience in AI, web3, and developing health tech products.
      • Shared mission: Building trust in Africa’s healthcare supply chain.
      • Shared love for building and learning fast.

11 of 12

Roadmap

Phase

Key Focus

Expected Outcome

Phase 1 — Manufacturer & Regulator Onboarding (Q1–Q2 2026)

Partner with key drug manufacturers and regulatory bodies (e.g., NAFDAC). Enable them to register and trace batches via Hedera Consensus Service.

Verified supply chain data and government-backed legitimacy.

Phase 2 — Pilot Rollout with Pharmacies & Hospitals (Q3 2026)

Deploy MediCheck verification dashboard to 3–5 hospitals and pharmacy chains. Integrate AI agent monitoring via HCS-10.

Early adoption, performance validation, and user feedback.

Phase 3 — Expansion & Incentive Layer (Q4 2026)

Introduce Hedera Token Service (HTS) for patient verification rewards and data-driven analytics for partners.

Broader market engagement and tokenized adoption growth.

12 of 12

Our Ask

      • Mentorship in large-scale Hedera deployment.
      • Partnerships with pharmaceutical manufacturers & regulators.
      • Funding to scale pilot to full MVP (manufacturing + distribution integration).

Goal:

Make drug verification as easy as scanning a QR code — for everyone, everywhere.